DK0623627T3 - Sulfonamidderivater - Google Patents

Sulfonamidderivater

Info

Publication number: DK0623627T3
Authority: DK; Denmark
Prior art keywords: cathepsin; sulfonamide; amyotrophia; calpain; hypercalcemia
Prior art date: 1993-04-28

Application number

DK94106225.9T

Other languages

English (en)

Inventor

Ryoichi Ando

Toshiro Sakaki

Chizuko Takahashi

Yoshiyuki Fujimura

Original Assignee

Mitsubishi Chem Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-04-28

Filing date

1994-04-21

Publication date

1997-04-28

1994-04-21 Application filed by Mitsubishi Chem Corp filed Critical Mitsubishi Chem Corp

1997-04-28 Application granted granted Critical

1997-04-28 Publication of DK0623627T3 publication Critical patent/DK0623627T3/da

Links

229940124530 sulfonamide Drugs 0.000 title abstract 2
150000003456 sulfonamides Chemical class 0.000 title abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
108010032088 Calpain Proteins 0.000 abstract 1
102000007590 Calpain Human genes 0.000 abstract 1
208000002177 Cataract Diseases 0.000 abstract 1
108090000712 Cathepsin B Proteins 0.000 abstract 1
102000004225 Cathepsin B Human genes 0.000 abstract 1
108090000619 Cathepsin H Proteins 0.000 abstract 1
102000004175 Cathepsin H Human genes 0.000 abstract 1
108090000624 Cathepsin L Proteins 0.000 abstract 1
102000004172 Cathepsin L Human genes 0.000 abstract 1
108010005843 Cysteine Proteases Proteins 0.000 abstract 1
102000005927 Cysteine Proteases Human genes 0.000 abstract 1
208000037147 Hypercalcaemia Diseases 0.000 abstract 1
208000001132 Osteoporosis Diseases 0.000 abstract 1
108090000526 Papain Proteins 0.000 abstract 1
239000004365 Protease Substances 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
230000000148 hypercalcaemia Effects 0.000 abstract 1
208000030915 hypercalcemia disease Diseases 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
201000000585 muscular atrophy Diseases 0.000 abstract 1
201000006938 muscular dystrophy Diseases 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1
235000019834 papain Nutrition 0.000 abstract 1
229940055729 papain Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Ophthalmology & Optometry (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Neurology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Neurosurgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)

DK94106225.9T 1993-04-28 1994-04-21 Sulfonamidderivater DK0623627T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP10278293		1993-04-28

Publications (1)

Publication Number	Publication Date
DK0623627T3 true DK0623627T3 (da)	1997-04-28

Family

ID=14336717

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK94106225.9T DK0623627T3 (da)	1993-04-28	1994-04-21	Sulfonamidderivater

Country Status (10)

Country	Link
US (1)	US5506243A (da)
EP (1)	EP0623627B1 (da)
JP (1)	JP3599287B2 (da)
AT (1)	ATE145214T1 (da)
CA (1)	CA2121523C (da)
DE (1)	DE69400887T2 (da)
DK (1)	DK0623627T3 (da)
ES (1)	ES2096370T3 (da)
GR (1)	GR3022524T3 (da)
TW (1)	TW261608B (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5872101A (en) *	1995-01-06	1999-02-16	Sibia Neurosciences, Inc.	Methods of treating neurodegenerative disorders using protease inhibitors
US5804560A (en) *	1995-01-06	1998-09-08	Sibia Neurosciences, Inc.	Peptide and peptide analog protease inhibitors
US6214800B1 (en)	1995-10-25	2001-04-10	Senju Pharmaceutical Co., Ltd.	Angiogenesis inhibitor
ES2190139T3 (es) *	1995-10-25	2003-07-16	Senju Pharma Co	Inhibidor de la angiogenesis.
EP0928786B1 (en) *	1995-10-25	2003-01-02	Senju Pharmaceutical Co., Ltd.	Angiogenesis inhibitor
WO1997021690A1 (en) *	1995-11-28	1997-06-19	Cephalon, Inc.	D-amino acid derived inhibitors of cysteine and serine proteases
US6653331B2 (en) *	1996-07-03	2003-11-25	Pharmacia & Upjohn Company	Targeted drug delivery using sulfonamide derivatives
AU3805497A (en) *	1996-07-19	1998-02-10	Neurotrauma Therapeutics, Inc.	Calpain inhibitors for the treatment of traumatic brain injury
WO1998003191A1 (en) *	1996-07-19	1998-01-29	Neurotrauma Therapeutics, Inc.	Calpain inhibitors for the treatment of cerebral ischemia, spinal cord injury or stroke
AU4489397A (en)	1996-10-31	1998-05-22	Alcon Laboratories, Inc.	The use of calpain inhibitors to treat ocular neural pathology
US5874449A (en) *	1996-12-31	1999-02-23	Gpi Nil Holdings, Inc.	N-linked sulfonamides of heterocyclic thioesters
NZ335480A (en) *	1996-12-31	2001-04-27	Guilford Pharm Inc	Neurotrophic low molecular weight N-linked sulfonamides of heterocyclic thioesters and their use as inhibitors of immunophilin proteins
AR013079A1 (es) *	1997-05-06	2000-12-13	Smithkline Beecham Corp	Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
BR9908566A (pt)	1998-03-05	2000-11-21	Senju Pharma Co	Composição farmacêutica para profilaxia e terapia de doenças associadas a citopatia do tecido do fundo ocular
AU1708099A (en)	1998-06-03	1999-12-20	Amgen, Inc.	N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres
US6331537B1 (en)	1998-06-03	2001-12-18	Gpi Nil Holdings, Inc.	Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
WO2000021550A2 (en) *	1998-10-13	2000-04-20	President And Fellows Of Harvard College	Methods and compositions for treating neurodegenerative diseases
US7253169B2 (en)	1999-11-12	2007-08-07	Gliamed, Inc.	Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en)	1999-11-12	2002-07-09	Gpi Nil Holdings, Inc.	AZA compounds, pharmaceutical compositions and methods of use
AU1464101A (en)	1999-12-21	2001-07-03	Gpi Nil Holdings, Inc.	Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
EP1254901A4 (en) *	2000-01-26	2003-03-05	Ono Pharmaceutical Co	5-CHAIN CYCLIC COMPOUNDS, CONTAINING NITROGEN, AND MEDICINAL PRODUCTS CONTAINING THE SAME AS ACTIVE INGREDIENTS
CA2417744A1 (en) *	2000-07-31	2002-02-07	The Regents Of The University Of California	Model for alzheimer's disease and other neurodegenerative diseases
EP1334718A4 (en) *	2000-10-26	2007-07-18	Senju Pharma Co	DRUG COMPOSITION CONTAINING DIPEPTIDYL ALDEHYDE COMPOUND
NZ538100A (en)	2000-12-13	2006-07-28	Arqule Inc	Heterocyclic sulfonamide inhibitors of beta amyloid production
ATE448198T1 (de) *	2002-07-22	2009-11-15	Senju Pharma Co	Neue alpha-ketoamidderivate und deren verwendung
US7662849B2 (en)	2003-06-04	2010-02-16	Virobay, Inc.	Amidino compounds as cysteine protease inhibitors
PT1663958E (pt)	2003-09-18	2015-06-01	Virobay Inc	Compostos contendo haloalquilo como inibidores de protease de cisteína
JP5154944B2 (ja)	2004-12-02	2013-02-27	ビロベイ，インコーポレイティド	システインプロテアーゼインヒビターとしてのスルホンアミド含有化合物
DK1865940T3 (da)	2005-03-21	2013-03-04	Virobay Inc	Alfaketoamidforbindelser som cysteinproteasehæmmere
CA2602112A1 (en)	2005-03-22	2006-09-28	Celera Genomics	Sulfonyl containing compounds as cysteine protease inhibitors
US20070203073A1 (en) *	2005-06-22	2007-08-30	Diamond Scott L	SARS and Ebola inhibitors and use thereof, and methods for their discovery
US7893112B2 (en)	2006-10-04	2011-02-22	Virobay, Inc.	Di-fluoro containing compounds as cysteine protease inhibitors
DK2079683T3 (da)	2006-10-04	2015-04-27	Virobay Inc	Di-fluorholdige forbindelser som cysteinproteasehæmmere
US8324417B2 (en)	2009-08-19	2012-12-04	Virobay, Inc.	Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
WO2019164852A1 (en) *	2018-02-20	2019-08-29	Edgewise Therapeutics, Inc.	Methods and compositions for treating movement disorders
JP7355777B2 (ja)	2021-03-31	2023-10-03	本田技研工業株式会社	切削工具
WO2024018245A1 (en)	2022-07-22	2024-01-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of calpain inhibitors for the treatment of the diabetic kidney disease
WO2024153744A1 (en)	2023-01-20	2024-07-25	Institut National de la Santé et de la Recherche Médicale	Autophagy activators for the treatment of rhabdomyolysis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5754157A (en) *	1980-09-19	1982-03-31	Nippon Kayaku Co Ltd	L-argininal derivative and its preparation
JP2701932B2 (ja) *	1989-04-10	1998-01-21	サントリー株式会社	タンパク質分解酵素阻害剤
EP0504938A3 (en) *	1991-03-22	1993-04-14	Suntory Limited	Prophylactic and therapeutic agent for bone diseases comprising di- or tripeptide derivative as active ingredient

1994
- 1994-04-05 JP JP6724294A patent/JP3599287B2/ja not_active Expired - Fee Related
- 1994-04-08 TW TW083103077A patent/TW261608B/zh active
- 1994-04-18 CA CA002121523A patent/CA2121523C/en not_active Expired - Fee Related
- 1994-04-21 DE DE69400887T patent/DE69400887T2/de not_active Expired - Fee Related
- 1994-04-21 DK DK94106225.9T patent/DK0623627T3/da active
- 1994-04-21 ES ES94106225T patent/ES2096370T3/es not_active Expired - Lifetime
- 1994-04-21 AT AT94106225T patent/ATE145214T1/de not_active IP Right Cessation
- 1994-04-21 EP EP94106225A patent/EP0623627B1/en not_active Expired - Lifetime
- 1994-04-28 US US08/233,963 patent/US5506243A/en not_active Expired - Fee Related
1997
- 1997-02-12 GR GR970400212T patent/GR3022524T3/el unknown

Also Published As

Publication number	Publication date
GR3022524T3 (en)	1997-05-31
EP0623627A1 (en)	1994-11-09
TW261608B (da)	1995-11-01
ATE145214T1 (de)	1996-11-15
CA2121523A1 (en)	1994-10-29
EP0623627B1 (en)	1996-11-13
DE69400887T2 (de)	1997-05-22
DE69400887D1 (de)	1996-12-19
ES2096370T3 (es)	1997-03-01
CA2121523C (en)	2006-06-20
JP3599287B2 (ja)	2004-12-08
US5506243A (en)	1996-04-09
JPH0748340A (ja)	1995-02-21

Publication	Publication Date	Title
DK0623627T3 (da)	1997-04-28	Sulfonamidderivater
ES2117088T3 (es)	1998-08-01	Derivados de aminocetonas.
CA2217737A1 (en)	1996-10-24	Thf-containing sulfonamide inhibitors of aspartyl protease
EP0810209A3 (en)	1998-12-02	Alpha - and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
EP0885887A3 (en)	1999-02-03	Sulfonamide inhibitors of HIV-Aspartyl protease
AP9600827A0 (en)	1997-10-17	Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease.
ATE406893T1 (de)	2008-09-15	Pharmazeutische zusammensetzung (kit) enthaltend dihydropyridinonverbindungen und eine verbindung mit immunmodulatorischer (oder antiinflammatorischer) wirkung und ihre verwendung
MY122696A (en)	2006-04-29	Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases.
NO20033918D0 (no)	2003-09-04	Ny anvendelse av peptidklasse av forbindelser for behandling av allodyni eller andre typer av kronisk smerte eller fantomsmerte
ATE528017T1 (de)	2011-10-15	Antimikrobiellen verbindungen und formulierungen
AU674378B2 (en)	1996-12-19	Use of 2-amino-6-A-propylamino-4,5,6, 7-tetrahydrobenzothiazole (pramipexol) as an anti-depressantdrug
DZ3008A1 (fr)	2004-03-27	Inhibiteurs de l'aspartyle protéase.
BR9809306A (pt)	2000-07-04	Inibidores de protease
EP1637139A3 (fr)	2006-08-16	Nouvelle utilisation de composés inhibiteurs de la protéase du VIH
NO974322D0 (no)	1997-09-19	DNA som koder for human papillomvirus type 18
ES2151168T3 (es)	2000-12-16	N-(2,4-dioxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3-il)-3-amidas.
FI970448L (fi)	1997-04-03	N-substituoituja 3-atsobisyklo(3.2.0)heptaanijohdannaisia,jotka ovat käyttökelpoisia neuroleptisina aineina
ES2177024T3 (es)	2002-12-01	Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
NO942983L (no)	1995-02-14	Farmasöytiske sammensetninger
ATE198475T1 (de)	2001-01-15	Lagerstabile wässrige lösungen von isothiazolin-3-onen
WO2002057246A3 (en)	2002-11-21	Inhibitors of cruzipain and other cysteine proteases
ATE277924T1 (de)	2004-10-15	Aryl-8-azabicyclo(3.2.1)octanes für die behandlung von depression
WO2002057248A3 (en)	2002-10-03	Inhibitors of cruzipain and other cysteine proteases
ES2127759T3 (es)	1999-05-01	Composiciones de detergentes.
ES555466A0 (es)	1987-05-01	Mejoras introducidas en el objeto de la patente de invencion 516.212 por perfeccionamientos introducidos en atomizadores agricolas